Actelion Pharmaceuticals US, Inc.

32 articles with Actelion Pharmaceuticals US, Inc.

• Beyond Batten Disease Foundation Announces Agreement with Actelion Pharmaceuticals Ltd to Provide Drug Product for BBDF-101

  3/2/2021

  Beyond Batten Disease Foundation is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, to provide Zavesca® for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease.

• Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal

  4/3/2020

  Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, today announced that CHEST, the official publication of the American College of Chest Physicians, published results from an expert Delphi consensus survey that help provide additional insights for physicians to advance the care of patients with pulmonary arterial hypertension (PAH).

• Actelion Withdraws Regulatory Filings to Extend the Indication of OPSUMIT® (macitentan 10mg) in CTEPH

  11/12/2019

  Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced its decision to voluntarily withdraw the European and other health authority filings still under review to extend the indication of OPSUMIT® (macitentan) to include the treatment of adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

• New OPSUMIT® (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with Pulmonary Arterial Hypertension

  10/21/2019

  OPSUMIT, as part of a combination regimen, reduced the primary endpoint of mean pulmonary vascular resistance by 47% at week 16 compared with baseline

• Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension

  5/20/2019

  Owlstone Medical announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.

• New Post-hoc Analysis Shows Adding UPTRAVI® (selexipag) Versus Placebo Improved Long-Term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatment Effect When Initiated Early

  5/20/2019

  Actelion presents latest post-hoc analysis from the GRIPHON study - the largest randomized, controlled, outcome trial ever conducted in patients with pulmonary arterial hypertension (PAH)   [20-May-2019]   ALLSCHWIL, Switzerland , May 20, 2019 /PRNewswire/ -- Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has presented

• Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

  3/26/2019

  Third Pole Therapeutics announced that it has entered into a strategic collaboration to work with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson.

• Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)

  3/15/2019

  Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today an interim analysis from the Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension (REPAIR) study of OPSUMIT®

• Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application

  1/16/2019

  Actelion Pharmaceuticals Ltd announced it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for OPSUMIT® (macitentan) in the treatment of adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) to improve pulmonary vascular resistance (PVR) and exercise capacity.

• Analytics 4 Life® and Actelion Enter Research Agreement to Develop New Diagnostics for Pulmonary Hypertension

  12/11/2018

  Research endeavor marks a clinical research expansion of the CorVista® platform

• Azafaros B.V. Secures Seed Funding to Develop New Treatments in Rare Metabolic Disorders

  7/23/2018

  Azafaros, today announced the closing of a seed financing round. BioGeneration Ventures (BGV) is the founding investor.

• Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

  4/30/2018

  Filing supported by data from MERIT-1 trial evaluating OPSUMIT in adults with inoperable CTEPH which showed significant improvements in pulmonary vascular resistance and six-minute walk distance (6MWD) compared with ongoing background therapy

• Actelion Pharmaceuticals US, Inc. Release: Europe's Largest Biopharmaceutical Company Takes Big Leap into Procurement-Powered Business Performance With Zycus

  9/4/2014

• Actelion Pharmaceuticals US, Inc. Nabs Ceptaris Therapeutics, Inc. in $250 Million Buyout Deal

  8/1/2013

• Actelion Ltd. Shareholders Reject Executive Pay Plan

  4/19/2013

• Federal Trade Commission Slams Actelion Pharmaceuticals US, Inc. for Withholding Samples

  3/13/2013

• Auxilium Pharmaceuticals and Actelion Pharmaceuticals US, Inc. Announce Approval of XIAFLEX® In Canada

  7/9/2012

• FDA Approves Actelion Pharmaceuticals US, Inc.'s SNDA for Second Generation VELETRI for Injection

  6/29/2012

• Auxilium Pharmaceuticals and Actelion Pharmaceuticals US, Inc. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico for Up to $68.5 Million

  2/23/2012

• Actelion Pharmaceuticals US, Inc. Floods FDA With Patient Death Reports

  10/6/2011